Spark Therapeutics (ONCE) Issues Earnings Results, Misses Expectations By $0.22 EPS

Spark Therapeutics (NASDAQ:ONCE) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.22), Fidelity Earnings reports. Spark Therapeutics had a negative net margin of 185.46% and a negative return on equity of 17.33%. The company had revenue of $10.70 million for the quarter, compared to the consensus estimate of $27.44 million. During the same period in the previous year, the business earned ($1.90) EPS. Spark Therapeutics’s revenue for the quarter was up 463.2% compared to the same quarter last year.

NASDAQ ONCE traded down $2.39 during trading on Tuesday, hitting $41.63. The company’s stock had a trading volume of 34,155 shares, compared to its average volume of 497,808. The company has a market cap of $1.70 billion, a PE ratio of -5.48 and a beta of 2.27. Spark Therapeutics has a fifty-two week low of $41.06 and a fifty-two week high of $96.59.

A number of hedge funds and other institutional investors have recently modified their holdings of ONCE. Russell Investments Group Ltd. boosted its holdings in Spark Therapeutics by 42.7% in the first quarter. Russell Investments Group Ltd. now owns 19,942 shares of the biotechnology company’s stock worth $1,328,000 after acquiring an additional 5,969 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Spark Therapeutics during the first quarter worth about $1,578,000. Fox Run Management L.L.C. acquired a new stake in shares of Spark Therapeutics during the second quarter worth about $533,000. Amalgamated Bank lifted its holdings in shares of Spark Therapeutics by 29.7% during the second quarter. Amalgamated Bank now owns 4,799 shares of the biotechnology company’s stock worth $397,000 after purchasing an additional 1,100 shares during the period. Finally, Aperio Group LLC lifted its holdings in shares of Spark Therapeutics by 23.5% during the second quarter. Aperio Group LLC now owns 5,543 shares of the biotechnology company’s stock worth $459,000 after purchasing an additional 1,056 shares during the period.

ONCE has been the topic of a number of recent research reports. William Blair reaffirmed a “buy” rating on shares of Spark Therapeutics in a research report on Friday, September 21st. Raymond James reaffirmed a “buy” rating on shares of Spark Therapeutics in a research report on Friday, September 21st. Guggenheim initiated coverage on Spark Therapeutics in a research report on Tuesday, October 9th. They set a “buy” rating and a $70.00 price objective on the stock. Zacks Investment Research downgraded Spark Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, October 13th. Finally, Citigroup raised Spark Therapeutics from a “neutral” rating to a “buy” rating in a research report on Tuesday, August 7th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $70.10.

WARNING: “Spark Therapeutics (ONCE) Issues Earnings Results, Misses Expectations By $0.22 EPS” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/11/06/spark-therapeutics-once-issues-earnings-results-misses-expectations-by-0-22-eps.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Featured Article: The benefits and drawbacks of dollar cost averaging

Earnings History for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply